|
UBE2T expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.96209999756303E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.2578999992493E-08 |
| Normal-vs-Stage2 |
3.946000E-02 |
| Normal-vs-Stage3 |
1.30040000001497E-06 |
| Normal-vs-Stage4 |
1.71959999994975E-06 |
| Stage1-vs-Stage2 |
2.22019999999157E-05 |
| Stage1-vs-Stage3 |
8.567000E-01 |
| Stage1-vs-Stage4 |
1.740440E-01 |
| Stage2-vs-Stage3 |
3.391600E-04 |
| Stage2-vs-Stage4 |
3.406700E-04 |
| Stage3-vs-Stage4 |
2.250200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.829199999832E-07 |
| Normal-vs-AfricanAmerican |
2.985300E-04 |
| Normal-vs-Asian |
1.50170000001726E-06 |
| Caucasian-vs-AfricanAmerican |
7.761000E-01 |
| Caucasian-vs-Asian |
8.520200E-01 |
| AfricanAmerican-vs-Asian |
8.480000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.37900000005431E-06 |
| Normal-vs-Female |
3.59599999777416E-08 |
| Male-vs-Female |
8.919200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.14900000625084E-09 |
| Normal-vs-Age(41-60Yrs) |
3.91399999999376E-06 |
| Normal-vs-Age(61-80Yrs) |
1.74984999999905E-05 |
| Normal-vs-Age(81-100Yrs) |
2.986500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.104900E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.360600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.564400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.417960E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.296610E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.544200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.555030E-01 |
| Classical-VS-Follicular |
4.580400E-03 |
| Classical-VS-Other |
8.814400E-01 |
| Classical-VS-Normal |
3.71899999684899E-08 |
| Tall-VS-Follicular |
2.921500E-03 |
| Tall-VS-Other |
5.822000E-01 |
| Tall-VS-Normal |
1.95180000051032E-07 |
| Follicular-VS-Other |
4.482400E-01 |
| Follicular-VS-Normal |
7.601800E-04 |
| Other-VS-Normal |
3.567600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.21059999999862E-06 |
| Normal-vs-N1 |
2.33969999996475E-06 |
| N0-vs-N1 |
1.739810E-01 |
|
|
